SCHEDULE 13G/A: StemPoint Capital Group Amends Significant Stake in Surrozen, Inc., Holding 15.8% of Common Stock

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have jointly filed an amendment to their Schedule 13G, disclosing a 15.8% beneficial ownership stake in Surrozen, Inc.'s common stock.

Summary

• The filing is an Amendment No. 2 to a Schedule 13G, indicating a change or update to a previously reported beneficial ownership.
• The reporting persons are StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross, acting as a group.
• As of March 31, 2025, the group beneficially owns an aggregate of 570,484 shares of Surrozen, Inc. Common Stock.
• This ownership represents 15.8% of Surrozen, Inc.'s class of securities.
• The total beneficial ownership includes 240,826 shares of common stock and 329,658 shares issuable upon the exercise of warrants.
• The calculation of the 15.8% ownership is based on 3,281,169 shares outstanding as of March 25, 2025, plus shares from Series E Warrants (up to 195,000), 2024 PIPE Warrants Series A (up to 70,158), and 2024 PIPE Warrants Series B (up to 64,500).
• The reporting persons hold shared voting power over 527,493 shares and shared dispositive power over 570,484 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Surrozen, Inc.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13G/A) reporting beneficial ownership. It contains no subjective language, performance metrics, or strategic updates that would indicate a positive or negative sentiment beyond the neutral act of reporting ownership.

Positives

• The disclosure of a significant 15.8% stake by an investment group like StemPoint Capital may signal confidence in Surrozen, Inc.'s long-term prospects.
• The filing explicitly states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control, indicating a passive investment approach.

Future Outlook

This Schedule 13G/A filing does not provide any forward-looking statements or guidance regarding Surrozen, Inc.'s future outlook.

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment group in a publicly traded company. It does not provide specific industry context or trends, but Surrozen, Inc. is typically associated with the biotechnology or pharmaceutical sector given its name and common stock structure.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership and confirms the passive nature of this investment group's stake in Surrozen, Inc.

Next Steps

• The reporting persons will file further amendments to this Schedule 13G if there are material changes to their beneficial ownership or investment intent in Surrozen, Inc.

Key Dates

Keywords

Surrozen Inc., StemPoint Capital, Beneficial Ownership, Schedule 13G/A, Common Stock, Warrants, Institutional Investor, SEC Filing